中国平安 PING AN 型V 让生产品后 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------|--------------------------|--------------------------------------------------------------------|-------|------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 证券研究报告 | | | | | | | | | | | 具备爆发潜力 | 安罗替尼肝癌、肾癌一线治疗数据优效， | | | | | | | | | | | | | | | | | | | | | 生物医药行业 | 强于大市（维持） | | | | | | | | | | 平安证券研究所 | 生物医药团队 | | | | | | ...